NEW YORK (AP) -- Shares of Immunomedics Inc. rose Thursday after an analyst said that the drug developer is on the brink of a licensing deal. Rodman & Renshaw analyst Elemer Piros said Immunomedics appears to be in “advanced” talks with a potential partner for its key lupus drug, based on his discussions with management.
